Galimedix, Inc. | WebDisclosure

Basculer en Français

9477	Companies
185475	Keywords
117817	Articles
99317	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 12/04/2025 at 20:20, 18 hours 17 minutes ago

Galimedix Therapeutics dévoile des résultats prometteurs de phase 1 pour le GAL-101

Résultats De La Phase 1 GAL-101 Traitement De La Maladie D'Alzheimer Barrière Hémato-encéphalique Planification De La Phase 2
BRIEF

published on 12/04/2025 at 20:20, 18 hours 17 minutes ago

Galimedix Therapeutics Reveals Promising Phase 1 Results for GAL-101

Phase 1 Results GAL-101 Alzheimer’s Treatment Blood-brain Barrier Phase 2 Planning
PRESS RELEASE

published on 12/04/2025 at 20:15, 18 hours 22 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Galimedix Therapeutics presents compelling Phase 1 study results at CTAD 2025, demonstrating excellent safety and pharmacokinetics of GAL-101, planning Phase 2 study in Alzheimer's disease

Alzheimer's Disease Galimedix Therapeutics GAL-101 Phase 1 Study CTAD 2025
BRIEF

published on 09/12/2025 at 13:25, 2 months 23 days ago

Galimedix fait progresser la recherche sur la maladie d'Alzheimer grâce à la réussite de la phase 1

Essai Clinique Galimedix Therapeutics Étude De Phase 1 Recherche Sur La Maladie D'Alzheimer Molécule GAL-101
BRIEF

published on 09/12/2025 at 13:25, 2 months 23 days ago

Galimedix Advances Alzheimer's Research with Successful Phase 1 Completion

Clinical Trial Galimedix Therapeutics Alzheimer's Research Phase 1 Study GAL-101 Molecule
PRESS RELEASE

published on 09/12/2025 at 13:20, 2 months 23 days ago

Progress in clinical development for Alzheimer´s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modul
Galimedix successfully completes Phase 1 study with GAL-101, a small molecule targeting amyloid beta in Alzheimer's disease. Phase 2 trial planned

Alzheimer's Disease Phase 2 Trial GAL-101 Phase 1 Study Galimedix
BRIEF

published on 05/21/2025 at 14:05, 6 months 15 days ago

Le GAL-201 de Galimedix s'avère prometteur dans le traitement de la maladie d'Alzheimer

GAL-201 Neuroinflammation Traitement De La Maladie D'Alzheimer Bêta-amyloïde Dommages Synaptiques
BRIEF

published on 05/21/2025 at 14:05, 6 months 15 days ago

Galimedix's GAL-201 Shows Promise in Alzheimer's Treatment

GAL-201 Neuroinflammation Alzheimer’s Treatment Amyloid-beta Synaptic Damage
PRESS RELEASE

published on 05/21/2025 at 14:00, 6 months 15 days ago

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease
Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

GAL-201 Galimedix Therapeutics Alzheimer’s Disease International Journal Of Molecular Sciences Neuroprotective Therapy
BRIEF

published on 05/06/2025 at 14:05, 6 months 30 days ago

Galimedix Therapeutics Completes Phase 1 Study with GAL-101

Alzheimer's Disease Galimedix Therapeutics GAL-101 Phase 1 Study AMD

1 2 ... 4

Accesswire

Published on 12/05/2025 at 14:00, 37 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 37 minutes ago

Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 02:35, 12 hours 2 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 12 hours 7 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 13 hours 37 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 14:22, 15 minutes ago

EQS-Adhoc: Jungheinrich AG: Jungheinrich expects to complete sale of its Russian subsidiary in 2026 and adjusts forecast for the 2025 financial year
Published on 12/05/2025 at 14:16, 20 minutes ago

Advanced Blockchain AG: Successful Completion of Token Generation Event of Portfolio company Talisman
Published on 12/05/2025 at 14:10, 27 minutes ago

The Kingdom of Saudi Arabia Launches a New Official Platform, "Saudi Properties", Ahead of the Non-Saudi Property Ownership Law
Published on 12/05/2025 at 13:45, 52 minutes ago

BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 1 hour 37 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting

Les Echos

Published on 12/05/2025 at 13:58, 39 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 5 hours 52 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 5 hours 52 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 5 hours 55 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 20 hours 22 minutes ago

Résiliation d'une convention conclue entre actionnaires

View all LES ECHOS COMFI WIRE